RGNX
REGENXBIO Inc.
stockNASDAQ
regenxbio is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (aav) gene therapy. regenxbio's nav® technology platform, a proprietary aav gene delivery platform, consists of exclusive rights to more than 100 novel aav vectors, including aav7, aav8, aav9 and aavrh10. regenxbio's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on regenxbio's nav technology platform. regenxbio seeks to accomplish this mission through a combination of internal development efforts and third‐party nav technology platform licensees.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 7.47 | 2026-09-28 | -0.47% | -0.450 |
| 1M | 8.94 | 2026-09-04 | -16.83% | 1.493 |
| 3M | 14.83 | 2026-07-06 | -49.87% | 1.870 |
| 6M | 8.80 | 2026-04-06 | -15.51% | 1.482 |
| 1Y | 10.43 | 2025-10-03 | -28.71% | 1.996 |
| 2Y | 9.72 | 2024-10-04 | -23.51% | — |
| 5Y | 32.33 | 2021-10-04 | -77.00% | 1.491 |
REGENXBIO Inc. (NASDAQ:RGNX) stock price today is $7.44, and today's volume is 1,036,886. RGNX is up 0.202% today. The 30 day average volume is 1.49M. RGNX market cap is $490.81M with 66.01M shares outstanding.